R. Qiu

发表

ABCC2-Mediated Biliary Transport of 4-Glutathionylcyclophosphamide and Its Contribution to Elimination of 4-Hydroxycyclophosphamide in Rat

J. Slattery, T. Kalhorn, R. Qiu, 2004, Journal of Pharmacology and Experimental Therapeutics.

Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: Prediction of exposure to the cyclophosphamide metabolite Carboxyethylphosphoramide mustard

P. Vicini, G. McDonald, J. Slattery, 2004, Clinical pharmacology and therapeutics.

Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients

T. Nicholas, M. Dowty, C. Banfield, 2022, Clinical pharmacology in drug development.

TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial.

E. Peeva, S. Forman, Y. Poulin, 2020, The Journal of investigative dermatology.

A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression.

T. Stiger, S. Kolluri, D. Feltner, 2008, The American journal of psychiatry.

Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis

Klaus Romero, Marc R. Gastonguay, William R. Gillespie, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

PF-04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: Translation from non-clinical species to healthy human volunteers

B. Corrigan, H. Soares, T. Nicholas, 2009, Alzheimer's & Dementia.

Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF‐06372865

Donal N. Gorman, R. M. Owen, J. V. van Gerven, 2018, British journal of pharmacology.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects

Jae Eun Ahn, R. Margolin, P. He, 2019, Journal of Alzheimer's disease : JAD.

Population Dose-Response Model for ADAS-cog Scores in Patients with Alzheimers Disease by Meta-Analysis of a Mixture of Summary and Individual Data

Brian Corrigan, Jonathan French, Kaori Ito, 2009 .

Aβ variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Aβ in healthy volunteers

H. Soares, T. Fullerton, M. Sikpi, 2009, Alzheimer's & Dementia.

Modeling and simulation of plasma Aβ in humans after multiple oral doses of PF-3084014, a potent gamma-secretase inhibitor

T. Fullerton, M. Gastonguay, S. Willavize, 2009, Alzheimer's & Dementia.

Pharmacokinetic and Pharmacodynamic Effects of a γ‐Secretase Modulator, PF‐06648671, on CSF Amyloid‐β Peptides in Randomized Phase I Studies

Jae Eun Ahn, T. Fullerton, É. Hajós‐Korcsok, 2019, Clinical pharmacology and therapeutics.

Minimization of CYP2D6 Polymorphic Differences and Improved Bioavailability via Transdermal Administration: Latrepirdine Example

G. Ranade, B. Corrigan, J. Mordenti, 2016, Pharmaceutical Research.

A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes

M. Whitlock, W. Esler, K. Khavandi, 2022, Diabetes, obesity & metabolism.

Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis

Kaori Ito, B. Corrigan, K. Romero, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial

V. Sikirica, E. Peeva, P. Mease, 2023, Arthritis & rheumatology.

Pharmacokinetics and Tolerability of Single and Multiple Doses of Desvenlafaxinein Healthy Korean Subjects

A. Płotka, Lee Ws, R. Qiu, 2016 .

The future is now: Model‐based clinical trial design for Alzheimer's disease

D Polhamus, L. Pani, B. Corrigan, 2015, Clinical pharmacology and therapeutics.